Navigation Links
CyberKnife Radiosurgery Used to Treat Lung Tumors at 90 Percent of Centers Worldwide
Date:3/26/2008

de them from eligibility for surgery to remove the tumors. The CyberKnife System gives doctors a new tool for attacking lung cancer without surgery. Combined with Accuray's Synchrony(R) Respiratory Tracking System and Xsight(R) Lung Tracking System, the CyberKnife System enables physicians to deliver radiation accurately, even while the patient breathes normally, and reduces the risk of damaging surrounding healthy tissues and critical structures. Because no actual surgery is needed, the CyberKnife is often a viable alternative for patients previously considered medically inoperable, and can be done on an outpatient basis.

"The CyberKnife System is giving new hope to lung cancer patients who may not have had any other options in the past," said Eric P. Lindquist, senior vice president and chief marketing officer at Accuray. "The CyberKnife System is well positioned to meet the growing need for lung cancer treatments as diagnoses of the disease are expected to increase exponentially around the world in the coming years."

CyberKnife centers in 12 countries are now treating lung cancer patients. The only country where the CyberKnife System is installed but not being used to treat lung cancer is Japan, where current regulatory approvals for the System are limited to treatments involving the head and neck.

* This statistic excludes Systems in Japan, where whole-body radiosurgery

is not yet approved by regulatory authorities.

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint pr
'/>"/>

SOURCE Accuray Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. CyberKnife Users Meeting Highlights Major Clinical Data Milestones and Emerging Trends
2. Varian Medical Systems Receives FDA 510(k) Clearance for High-Definition Collimator That Enables Ultra-Fine Intensity-Modulated Radiosurgery
3. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
4. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
8. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
9. FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
10. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
11. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... Contract Research Organization XenoTech, LLC , a ... new 41,500 ft2 facility. The planned move will double ... W. 116th St. in Lenexa, KS. The new facility, ... space, will remain in the Kansas City metro area, just ... twenty years ago. Remaining in the Kansas City area ...
(Date:4/21/2015)... April 21, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... multi-arm Phase 1 study of MM-141, a bispecific antibody ... an oral session by Dr. Mansoor Saleh , ... Annual Meeting in Philadelphia, PA. ... as a monotherapy and in combination with everolimus or ...
(Date:4/21/2015)... 21, 2015  Cryoport, Inc. (OTCBB: CYRX) ... logistics solutions for the life sciences industry, ... lines, clinical research organizations, vaccine manufacturers and ... Mark W. Sawicki , Chief Commercial Officer, ... Summit in San Francisco, CA ...
(Date:4/21/2015)... April 21, 2015 PRC Clinical, ... and exhibit at the ACRP 2015 Global Conference and ... Utah. The Association of Clinical Research Professionals (ACRP) Global ... conference solely focused on the conduct of clinical trials. ... development, and widely recognized industry certifications. , The ...
Breaking Biology Technology:XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014 2XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014 3First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 2First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 3First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 4First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 5Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 3PRC Clinical Sponsors The ACRP 2015 Global Conference And Meets Biotech Companies in the Salt Lake City Area. 2
... Pharma, Inc., a privately-,held, specialty pharmaceutical company, announced ... A financing, which included investors Domain Associates,Latterell Venture ... is committed to the development of prescription,products based ... the unmet,needs of patients and their caregivers. Meritage ...
... Gen-Probe Incorporated,(Nasdaq: GPRO ) announced today that the ... Annual Growth Stock on Wednesday, June 18, 2008 at,approximately ... be,webcast live and may be accessed through a link ... http://www.gen-probe.com . The webcast will be,available for 30 days ...
... - Potential to combine compounds with multiple new and existing ... with activity ... against drug-resistant organisms -, SAN DIEGO and LONDON, June ... have entered into a,worldwide strategic alliance for the discovery, development ...
Cached Biology Technology:Meritage Pharma, Inc. Announces Company Formation and $22.5M Series A Financing 2Gen-Probe to Webcast Presentation at the William Blair & Company 28th Annual Growth Stock Conference 2GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections 2GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections 3GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections 4GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections 5
(Date:4/13/2015)... 13, 2015  higi, a leading cloud-based consumer engagement ... fully engage with their communities around health and wellness, ... and secure API.  ... accessible, affordable, and convenient vehicle to receive validated health ... The API will allow higi,s trusted partners, ...
(Date:4/9/2015)... Calif. , April 9, 2015 Synaptics ... interface solutions, announced today that it will report financial ... Thursday, April 23, 2015, after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:4/6/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market, announced today ... MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND SYSTEM FOR ... introduces a new revolutionary method and system to ... of miniature antenna modules for multiple purposes including ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... Extra genomes appear, on average, to offer no benefit or ... the origin of new species, say scientists from Indiana University ... of the National Academy of Sciences . Plant biologists ... chromosome sets -- was a gateway to speciation. But the ...
... Folsom, CA August 11, 2009 On Monday, August ... 90th Annual Pacific Division Meeting of the AAAS in San ... science communication from some of the brightest minds in the ... Part of the Job: Communicating Science to the Public. (Online ...
... at Oregon State University have discovered that the circadian rhythms ... more susceptible to pesticides at some times of the day ... it may be possible to tap into this genetic characteristic, ... to a specific pesticide, and use that information to increase ...
Cached Biology News:Genome duplication responsible for more plant species than previously thought 2Genome duplication responsible for more plant species than previously thought 3Science communication to take the stage at annual AAAS meeting in San Francisco 2Biological clocks of insects could lead to more effective pest control 2Biological clocks of insects could lead to more effective pest control 3
Luminometers...
...
Cell Lysis Buffer is used to lyse cells under nondenaturing conditions....
LECHNER AND LaVECK MEDIUMfor the clonal growth of normal human bronchial and other epithelial cells. Requires additives. With glutamine.Recommended storage condition:oC to 8oCIntended use(s):research...
Biology Products: